CD274 and neoplasm: Similarly, the oral administration of Bifidobacterium bifidum combined with an anti-PD-L1 agent almost completely suppressed tumor development in a preclinical mouse study, suggesting improvement in microbiota-driven immunotherapy [124] (Fig. 8).